Loading...
XNAS
ICLR
Market cap12bUSD
Apr 04, Last price  
153.72USD
1D
-6.04%
1Q
-27.93%
Jan 2017
104.41%
Name

ICON PLC

Chart & Performance

D1W1MN
P/E
15.68
P/S
1.50
EPS
9.80
Div Yield, %
Shrs. gr., 5y
8.85%
Rev. gr., 5y
24.17%
Revenues
8.28b
+1.99%
0455,597,000630,722,000865,248,000887,612,000900,044,000945,729,0001,115,006,0001,336,058,0001,503,316,0001,574,978,0001,666,487,0001,758,439,0002,595,777,0002,805,839,0002,797,288,0005,480,826,0007,741,386,0008,120,176,0008,281,675,999
Net income
791m
+29.26%
038,304,00055,963,00078,120,00094,299,00087,071,00022,880,00058,346,000102,812,000172,468,000239,539,000262,179,000272,944,000322,817,000373,986,000327,809,000153,185,000505,304,000612,335,000791,474,000
CFO
1.29b
+10.82%
25,209,00050,452,00042,966,00081,282,000255,070,00087,428,00020,191,000113,771,000221,227,000169,948,000279,531,000259,204,00048,741,000264,013,000412,541,000594,724,000829,142,000563,315,0001,161,027,0001,286,652,000
Earnings
Apr 22, 2025

Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including early development, patient recruitment and retention, strategy and analytics, late phase research, data and technology solution, and consulting and analytics services. The company's clinical development services also comprise medical imaging, clinical research and laboratory services, project management, site monitoring and management services, data management, biostatistics and programming, medical writing and publishing, medical affair, endpoint adjudication/data monitoring committees, pharmacovigilance, interactive response technologies, clinical supplies management, strategic regulatory, medical communication, and consulting and advisory services. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company was incorporated in 1990 and is headquartered in Dublin, Ireland.
IPO date
May 15, 1998
Employees
41,160
Domiciled in
IE
Incorporated in
IE

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
8,281,676
1.99%
8,120,176
4.89%
7,741,386
41.24%
Cost of revenue
5,845,319
5,719,949
5,527,045
Unusual Expense (Income)
NOPBT
2,436,357
2,400,227
2,214,341
NOPBT Margin
29.42%
29.56%
28.60%
Operating Taxes
77,710
11,749
59,411
Tax Rate
3.19%
0.49%
2.68%
NOPAT
2,358,647
2,388,478
2,154,930
Net income
791,474
29.26%
612,335
21.18%
505,304
229.87%
Dividends
Dividend yield
Proceeds from repurchase of equity
(499,998)
50,957
(64,156)
BB yield
2.87%
-0.22%
0.40%
Debt
Debt current
29,762
146,564
55,150
Long-term debt
3,676,568
3,954,495
4,862,325
Deferred revenue
Other long-term liabilities
209,304
232,652
277,448
Net debt
3,109,597
3,674,199
4,594,363
Cash flow
Cash from operating activities
1,286,652
1,161,027
563,315
CAPEX
(168,060)
(140,692)
(142,160)
Cash from investing activities
(266,790)
(226,653)
(145,867)
Cash from financing activities
(837,183)
(844,043)
(864,173)
FCF
2,415,699
2,334,972
1,875,148
Balance
Cash
538,785
380,056
290,481
Long term investments
57,948
46,804
32,631
Excess cash
182,649
20,851
Stockholders' equity
2,502,768
2,298,074
1,656,495
Invested Capital
13,115,899
13,390,868
13,519,459
ROIC
17.80%
17.75%
16.06%
ROCE
17.27%
16.77%
15.26%
EV
Common stock shares outstanding
83,032
82,718
82,468
Price
209.71
-25.92%
283.07
45.72%
194.25
-37.28%
Market cap
17,412,730
-25.63%
23,414,882
46.17%
16,019,480
-24.01%
EV
20,522,327
27,089,081
20,613,843
EBITDA
2,948,390
2,986,177
2,783,854
EV/EBITDA
6.96
9.07
7.40
Interest
237,237
336,699
229,731
Interest/NOPBT
9.74%
14.03%
10.37%